Current Clinical Trials
Find a Clinical Trial
A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants."
| Therapeutic Area | Condition | Study Number |
Description | Status (Click on link to learn more) |
| COVID-19 | COVID-19 | CSL312_COVID-19 | A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) | Recruiting |
| COVID-19 | CSL324_COVID-19 | CSL324 in COVID-19 | Not Yet Recruiting | |
| Haematology and Thrombosis |
Hemophilia A | CSL627_3001 | An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A | Active, Not Recruiting |
| Hemophilia B | CSL654_3003 | A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B | Active, Not Recruiting | |
| Reversal of acquired coagulation factor deficiency | BE1116_4001 | An Observational Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding | Recruiting | |
| Sickle Cell | CSL200_1001 | CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease | Recruiting | |
| Sickle Cell | CSL889_1001 | A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease | Not Yet Recruiting | |
| Cardiovascular and Metabolic | Acute Coronary Syndrome | CSL112_3001 | Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) | Recruiting |
| Diabetic Kidney Disease | CSL346_2001 | A Phase 2a Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease | Recruiting | |
| Immunology and Neurology | Dermatomyositis (DM) | IgPro20_3007 | A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM) | Recruiting |
| Pediatric CIDP | IgPro10_4002 | Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP | Recruiting | |
| Hereditary Angioedema (HAE) | CSL312_2001 | A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) | Active, Not Recruiting | |
| Hereditary Angioedema (HAE) | CSL830_3003 | A Phase 3 study to evaluate clinical efficacy, safety, and pharmacokineti00cs of subcutaneous administration of human plasma derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema in Japanese subjects | Recruiting | |
| Hidradenitis Suppurativa and Palmoplantar Pustulosis | CSL324_1002 | A study of the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis | Recruiting | |
| Systemic Sclerosis | IgPro10_2001 | Efficacy and safety study of IgPro10 in adults with Systemic Sclerosis | Active, Not Recruiting | |
| Systemic Sclerosis | IgPro20_2001 | A study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in subjects with diffuse cutaneous systemic sclerosis (dcSSc) | Recruiting | |
| Healthy Subjects | CSL324_1003 | Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | Not Yet Recruiting | |
| Healthy Subjects | CSL730_1001 | Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults | Cancelled | |
| Healthy Subjects | CSL730_1002 | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects | Recruiting | |
| Respiratory | Mild Asthma | CSL311_1001 | A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma. | Active, Not Recruiting |
| alpha-1 antitrypsin deficiency | AmAREtTI Study | Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage) | Recruiting | |
| Transplant | Antibody-mediated kidney transplant rejection | CSL842_3001 | Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients | Active, Not Recruiting |
| Antibody-mediated kidney transplant rejection | CSL300_3001 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients | Recruiting | |
| Acute GVHD (aGVHD) | CSL964_2001 | The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE) | Recruiting | |
| Graft Versus Host Disease (GVHD) | CSL964_5001 | A study on the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD | Recruiting | |
|
COMPLETED STUDIES: |
||||
| Haematology and Thrombosis | Congenital Fibrinogen Deficiency | BI3023_4003 | An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency | Completed |
| Von Willebrand Disease | CSLCT-BIO-12-83 | Study of Voncento® in Subjects With Von Willebrand Disease | Completed | |
| Cardiovascular and Metabolic | Coronary Heart Disease | CSL112_1001 | Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults | Completed |
| Renal Impairment and Acute Myocardial Infarction | CSL112_2001 | A Phase 2 Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction | Results | |
| Immunology and Neurology | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | IgPro20_3004 | Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Results |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | IgPro10_5004 | Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1) | Completed | |
| HIV-1 | CAL-USA-11 | An Adaptive Phase I/II Study of the Safety of CAL-USA-11 in HIV-1 Infected Adults Previously Exposed to ART | Results | |
| Primary Immune Deficiency (PID) | IgPro20_1001 | Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump | Completed | |
| Primary Immune Deficiency (PID) | IgPro20_4004 | Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) | Results | |
| Primary Immune Deficiency (PID) | IgPro20_4005 | Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules | Results | |
| Healthy Subjects | CSL324_1001 | Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults | Completed | |